Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:03:36.237Z.
Calculation as of: 2026-10-06T17:03:36.237Z.
Quote observation: 2026-10-06T16:44:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 11162aacdea541bd0c22d895134fbf2d0042bdecc45a18e93c77b8e06c908ab2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OneMedNet Corporation (ONMD) | $29.16M | N/A | N/A | N/A | N/A |
| Quantum Cyber N.V. (QUCY)vs › | $29.48M | N/A | N/A | N/A | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $29.54M | N/A | N/A | N/A | N/A |
| BeyondSpring Inc. (BYSI)vs › | $29.65M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.37M | N/A | N/A | N/A | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $29.95M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $30.00M | N/A | 0.36x | 0.82x | 0.82x |
| InspireMD, Inc. (NSPR)vs › | $28.10M | N/A | N/A | N/A | N/A |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.74M | N/A | N/A | N/A | N/A |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $30.69M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute